Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | USP2 | O75604 | 1/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | GAPDH | P04406 | 2/20 | 0.51 |
| ▸ | P2RY2 | P41231 | 4/20 | 0.49 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.43 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.43 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL532526 | 1.00 | MEN1 (0.67) | MEN1USP2POLBKMT2ALMNA | |
| SCHEMBL12755327 | 1.00 | MEN1 (0.67) | MEN1USP2POLBKMT2ALMNA | |
| SCHEMBL12352444 | 1.00 | MEN1 (0.67) | MEN1USP2POLBKMT2ALMNA | |
| SCHEMBL29989951 | 0.98 | MEN1 (0.63) | MEN1USP2POLBKMT2ALMNA | |
| SCHEMBL22992612 | 0.96 | MEN1 (0.71) | MEN1USP2POLBKMT2ALMNA | |
| SCHEMBL19326815 | 0.96 | MEN1 (0.71) | MEN1USP2POLBKMT2ALMNA | |
| SCHEMBL9221115 | 0.96 | MEN1 (0.71) | MEN1USP2POLBKMT2ALMNA | |
| SCHEMBL22992319 | 0.96 | MEN1 (0.71) | MEN1USP2POLBKMT2ALMNA | |
| SCHEMBL23906728 | 0.96 | MEN1 (0.71) | MEN1USP2POLBKMT2ALMNA | |
| SCHEMBL10459898 | 0.96 | MEN1 (0.71) | MEN1USP2POLBKMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2415776-B1 | Beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B | NOVARTIS AG (CH) | 2016-05-25 | — | — | EP | disclosed |
| US-9290533-B2 | β-L-2′-deoxy-nucleosides for the treatment of hepatitis B | NOVARTIS AG (CH) | 2016-03-22 | — | — | US | disclosed |
| EP-1572095-B1 | BETA-L-2'-DEOXYNUCLEOSIDES FOR USE IN THE TREATMENT OF RESISTANT HBV STRAINS | NOVARTIS AG (CH) | 2015-06-10 | — | — | EP | disclosed |
| EP-1431304-B1 | Beta - L-2'-Deoxy-Nucleosides for the treatment of Hepatitis B | NOVARTIS AG (CH) | 2014-12-03 | — | — | EP | disclosed |
| US-20130324491-A1 | BETA-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B | IDENIX PHARMACEUTICALS, INC. (US) | 2013-12-05 | — | — | US | disclosed |
| US-20120264707-A1 | BETA-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B | IDENIX PHARMACEUTICALS, INC. (US) | 2012-10-18 | — | — | US | disclosed |
| US-8158606-B2 | β-L-2′-deoxynucleosides for the treatment of resistant HBV strains and combination therapies | NOVARTIS, AG (CH) | 2012-04-17 | — | — | US | disclosed |
| EP-2415776-A1 | Beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B | IDENIX Pharmaceuticals, Inc. (US) | 2012-02-08 | — | — | EP | disclosed |
| US-20110257120-A1 | BETA-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B | IDENIX PHARMACEUTICALS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110195922-A9 | Beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B | IDENIX PHARMACEUTICALS, INC. (US) | 2011-08-11 | — | — | US | disclosed |
| US-6787526-B1 | AND INTERFERON | IDENIX PHARMACEUTICALS, INC. | 2004-09-07 | — | — | US | disclosed |
| EP-1431304-A2 | Beta - L-2'-Deoxy-Nucleosides for the treatment of Hepatitis B | Idenix (Cayman) Limited (KY) | 2004-06-23 | — | — | EP | disclosed |
| US-20030225028-A1 | 2'-deoxy-beta-L-erythropentofuranonucleoside or a salt or prodrug thereof | GOSSELIN GILLES (FR) | 2003-12-04 | — | — | US | disclosed |
| US-20030220290-A1 | Beta-L-2'-deoxy-nucleosides for the treatment of hepatitis B | CENTRE NATIONAL DA LA RESERCHE SCIENTIFIQUE | 2003-11-27 | — | — | US | disclosed |
| US-6596700-B2 | Administering a 2'-deoxy-beta-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof | IDENIX PHARMACEUTICALS INC. | 2003-07-22 | — | — | US | disclosed |
| US-6569837-B1 | Administering 2'-deoxy-beta-L-erythro-pentofuranonucleoside alone or with another anti-hepatitis B agent such as 3TC (beta-L-2-hydroxymethyl-5-(cytosin-1-yl)-1,3-oxathiolane); use of beta-l-thymidine (telbivudine) | IDENIX PHARMACEUTICALS INC. | 2003-05-27 | — | — | US | disclosed |
| US-6566344-B1 | Administering beta-L-2'-deoxycytidine compound for therapy of hepatitis B virus infection | IDENIX PHARMACEUTICALS, INC. | 2003-05-20 | — | — | US | disclosed |
| US-6444652-B1 | β-L-2'-deoxy-nucleosides for the treatment of hepatitis B | NOVIRIO PHARMACEUTICALS LIMITED (CY) | 2002-09-03 | — | — | US | disclosed |
| US-6395716-B1 | Antivirals such as telbivudine | NOVIRIO PHARMACEUTICALS LIMITED (KY) | 2002-05-28 | — | — | US | disclosed |
| US-20020035085-A1 | Administering a 2'-deoxy-beta-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof | NOVARTIS AG (CH) | 2002-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257120-A1 | BETA-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B | PNP, DUT, ATIC | MEN1 4849/4885USP2 3759/4885POLB 65/4885 |
| US-20020035085-A1 | Administering a 2'-deoxy-beta-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof | DCTD, DUT, DPYD | MEN1 4176/4885USP2 2950/4885POLB 207/4885 |
| US-20030225028-A1 | 2'-deoxy-beta-L-erythropentofuranonucleoside or a salt or prodrug thereof | ATIC, DUT, GART | MEN1 4680/4885USP2 4134/4885POLB 174/4885 |
| US-20130324491-A1 | BETA-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B | PNP, DUT, ATIC | MEN1 4849/4885USP2 3759/4885POLB 65/4885 |
| US-20110195922-A9 | Beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B | PNP, DUT, ATIC | MEN1 4849/4885USP2 3759/4885POLB 65/4885 |
| US-20120264707-A1 | BETA-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B | PNP, DUT, ATIC | MEN1 4849/4885USP2 3759/4885POLB 65/4885 |
| US-20030220290-A1 | Beta-L-2'-deoxy-nucleosides for the treatment of hepatitis B | DUT, PNP, ATIC | MEN1 4820/4885USP2 3959/4885POLB 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.